Pediatric Micra leadless pacemaker implantation via internal jugular and femoral veins: experience with 11 patients.


Journal

Future cardiology
ISSN: 1744-8298
Titre abrégé: Future Cardiol
Pays: England
ID NLM: 101239345

Informations de publication

Date de publication:
09 2022
Historique:
pubmed: 18 8 2022
medline: 9 9 2022
entrez: 17 8 2022
Statut: ppublish

Résumé

In pediatrics, conventional transvenous and epicardial pacemaker systems carry complications, such as lead distortion due to growth and activity, in addition to lead and pocket complications. A retrospective review of pediatric leadless pacing at the University of Minnesota Masonic Children's Hospital (MN, USA) from 2018 through 2021 was performed. Diagnoses, rationale for pacing, demographics, pacing thresholds and longevity of devices were recorded. Twelve leadless pacemaker insertions and one removal were performed successfully in patients weighing 19-90 kg. Six patients had Micra implantation via the internal jugular vein without surgical cut-down. Up to 3 years of follow-up were noted, with median follow-up of 22 months. No late complications occurred. Leadless pacemaker implantation and early retrieval were feasible in pediatric patients. Pacemaker placement has been the standard of care for patients when the top and bottom chambers of the heart are not communicating electrically. Patients can either be born with this, or it can happen after heart surgery. Traditional pacemaker technique involves placing wires (leads) through veins to the heart and surgically implanting a generator in the body. This carries a risk of complications, mainly lead dislocation and fracture with growth and activity. The Micra leadless pacemaker mitigates this risk and can be implanted into the muscle of the right ventricle. There are currently only small case series and reports in the literature on Micra pacemaker implantation in pediatric patients with congenital heart disease. We implanted 12 such devices in 11 pediatric patients weighing 19–90 kg. Six of these implantations were deployed using the internal jugular vein and were successful. One patient had a pericardial effusion at the time of implantation. Overall, leadless pacemaker implantation in the pediatric population with congenital heart disease is feasible, but further data are needed to assess long-term safety.

Autres résumés

Type: plain-language-summary (eng)
Pacemaker placement has been the standard of care for patients when the top and bottom chambers of the heart are not communicating electrically. Patients can either be born with this, or it can happen after heart surgery. Traditional pacemaker technique involves placing wires (leads) through veins to the heart and surgically implanting a generator in the body. This carries a risk of complications, mainly lead dislocation and fracture with growth and activity. The Micra leadless pacemaker mitigates this risk and can be implanted into the muscle of the right ventricle. There are currently only small case series and reports in the literature on Micra pacemaker implantation in pediatric patients with congenital heart disease. We implanted 12 such devices in 11 pediatric patients weighing 19–90 kg. Six of these implantations were deployed using the internal jugular vein and were successful. One patient had a pericardial effusion at the time of implantation. Overall, leadless pacemaker implantation in the pediatric population with congenital heart disease is feasible, but further data are needed to assess long-term safety.

Identifiants

pubmed: 35975839
doi: 10.2217/fca-2021-0139
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

679-686

Auteurs

Amr El-Bokl (A)

Department of Pediatric Cardiology, University of Minnesota/Masonic Children's Hospital, Minneapolis, MN 55454, USA.

Hani Siddeek (H)

Department of Pediatric Cardiology, University of Utah, Salt Lake City, UT 84112, USA.

Cody Hou (C)

Department of Pediatric Cardiology, University of Minnesota/Masonic Children's Hospital, Minneapolis, MN 55454, USA.

Alison Leslie (A)

Department of Pediatric Cardiology, University of Minnesota/Masonic Children's Hospital, Minneapolis, MN 55454, USA.

Erick Jimenez (E)

Department of Pediatric Cardiology, Cincinnati Children's Hospital, Cincinnati, OH 45229, USA.

Daniel Cortez (D)

Department of Pediatric Cardiology, University of Minnesota/Masonic Children's Hospital, Minneapolis, MN 55454, USA.
Department of Pediatric Cardiology, UC Davis Medical Center, Sacramento, CA 95817, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH